查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596449

骨骼发育不良市场：按类型、治疗和最终用户划分 - 全球预测 2025-2030

Skeletal Dysplasia Market by Type (Achondroplasia, Fibrodysplasia Ossificans Progressive, Hypophosphatasia), Treatment (Medication, Surgery), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年骨骼发育不良市场价值为28.3亿美元，预计到2024年将达到30.3亿美元，复合年增长率为7.20%，到2030年将达到46.1亿美元。

骨骼发育不良包括一组以骨骼和软骨生长异常为特征的遗传性疾病，导致身材矮小和各种骨骼异常。骨骼发育不良市场是由对准确诊断、治疗方案以及基因检测和分子诊断的进步日益增长的需求所推动的。这些疾病需要专门的医疗干预，使其成为医疗保健提供者、研究人员和製药公司的重要市场。应用包括诊断影像、遗传咨询以及基因治疗和标靶药物等创新治疗方法。该市场主要面向医院、研究中心和专科诊所。关键的成长要素包括由于检出率提高、对罕见遗传疾病认识的提高以及基因组学和个人化医疗的技术进步而导致盛行率增加。潜在的商机在于开发新疗法、提高诊断准确性以及利用 CRISPR 和其他基因编辑技术。企业应专注于与基因研究机构合作，投资针对特定突变的罕见疾病药物的研发。然而，市场成长面临限制，包括治疗成本上升、孤儿药物核准的监管障碍以及对罕见疾病异质性的了解有限。挑战包括对基因治疗的伦理担忧以及患者对现有治疗方法的不同反应。创新机会包括非侵入性基因检测、病患管理预测分析和骨再生研究。公司应该投资扩大产品范围，包括客製化基因测试，并与医疗保健 IT 公司合作，整合人工智慧进行预测诊断。该市场是研究集中市场，并受到监管环境的影响，在精准医学进步的支持下，个人化治疗计划成为趋势。为了取得成功，公司必须驾驭复杂的监管途径，同时确保患者可近性并实施强调早期准确诊断价值的意识计划。

主要市场统计
基准年[2023] 28.3亿美元
预测年份 [2024] 30.3亿美元
预测年份 [2030] 46.1亿美元
复合年增长率（%） 7.20%

市场动态：快速发展的骨骼发育不良市场的关键市场洞察

供需的动态交互作用正在改变骨骼发育不良市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 先天性疾病和出生缺陷的增加
    • 荷尔蒙疗法治疗骨骼发育不良的进展
    • 关注骨骼发育不良设备的技术进步
  • 市场限制因素
    • 骨骼发育不良的治疗选择有限
  • 市场机会
    • 增加骨骼发育不良药物开发的研发和临床试验
  • 市场挑战
    • 缺乏有效的诊断工具和技术

波特五力：开拓骨骼发育不良市场的策略工具

波特的五力框架是了解骨骼发育不良市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨骼发育不良市场的外部影响

外部宏观环境因素在塑造骨骼发育不良市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解骨骼发育不良市场的竞争状况

对骨骼发育不良市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵骨骼发育不良市场供应商的绩效评估

FPNV 定位矩阵是评估骨骼发育不良市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製骨骼发育不良市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对骨骼发育不良市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 先天性疾病和出生缺陷的增加
      • 荷尔蒙疗法治疗骨骼发育不良的进展
      • 关注骨骼发育不良设备的技术进步
    • 抑制因素
      • 骨骼发育不良的治疗选择有限
    • 机会
      • 增加药物开发的研发和临床试验骨骼发育不良
    • 任务
      • 缺乏有效的诊断工具和技术
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章骨骼发育不良市场：依类型

  • 软骨发育不全
  • 进行性肌肉骨化症
  • 低磷酸酯酶症
  • 多发性骨软骨瘤
  • X连锁低血磷症

第七章 骨骼发育不良市场治疗市场治疗

  • 药物治疗
  • 外科手术

第八章骨骼发育不良市场：依最终用户分类

  • 诊所
  • 医院

第九章北美及南美骨骼发育不良市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区骨骼发育不良市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的骨骼发育不良市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Amgen, Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • BioMarin Pharmaceutical Inc.
  • Celgene Corporation
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-AD36CD89842F

The Skeletal Dysplasia Market was valued at USD 2.83 billion in 2023, expected to reach USD 3.03 billion in 2024, and is projected to grow at a CAGR of 7.20%, to USD 4.61 billion by 2030.

Skeletal dysplasia encompasses a group of genetic disorders characterized by abnormalities in bone and cartilage growth, leading to disproportionate short stature and various skeletal anomalies. The market for skeletal dysplasia is driven by the growing need for accurate diagnosis, treatment options, and advancements in genetic testing and molecular diagnostics. These disorders necessitate specialized medical interventions, making the market critical for healthcare providers, researchers, and pharmaceutical companies. The application scope includes diagnostic imaging, genetic counseling, and innovative therapeutic approaches like gene therapy and targeted drugs. The market caters primarily to hospitals, research centers, and specialty clinics. Key growth factors include increasing prevalence due to improved detection rates, heightened awareness of rare genetic disorders, and technological advancements in genomics and personalized medicine. Potential opportunities lie in developing novel therapeutics, enhancing diagnostic accuracy, and leveraging CRISPR and other gene-editing technologies. Companies should focus on collaborations with genetic research institutions and invest in R&D for orphan drugs tailored to specific mutations. However, market growth faces limitations such as high costs of treatment, regulatory hurdles for orphan drug approvals, and limited understanding of disease heterogeneity due to its rarity. Challenging factors include ethical concerns regarding genetic treatments and variable patient responses to existing therapies. Innovation opportunities point towards non-invasive genetic testing, predictive analytics for patient management, and bone regeneration research. Businesses should capitalize on expanding their product offerings to include tailored genetic tests and collaborate with healthcare IT firms to integrate AI for predictive diagnostics. The market is research-intensive and shaped by regulatory landscapes, with a trend moving towards personalized treatment plans supported by advancements in precision medicine. To succeed, companies must navigate complex regulatory pathways while ensuring patient accessibility and awareness programs that highlight the value of early and accurate diagnosis.

KEY MARKET STATISTICS
Base Year [2023] USD 2.83 billion
Estimated Year [2024] USD 3.03 billion
Forecast Year [2030] USD 4.61 billion
CAGR (%) 7.20%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Skeletal Dysplasia Market

The Skeletal Dysplasia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing congenital disorders and birth defects
    • Growth in hormone therapy for treatment of skeletal dysplasia
    • Focus on the technological advancements in skeletal dysplasia devices
  • Market Restraints
    • Limited treatment options available for skeletal dysplasia
  • Market Opportunities
    • Increasing R&D and clinical trial for drug development of skeletal dysplasia
  • Market Challenges
    • Lack of efficient diagnostic measures and technologies

Porter's Five Forces: A Strategic Tool for Navigating the Skeletal Dysplasia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Skeletal Dysplasia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Skeletal Dysplasia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Skeletal Dysplasia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Skeletal Dysplasia Market

A detailed market share analysis in the Skeletal Dysplasia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Skeletal Dysplasia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Skeletal Dysplasia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Skeletal Dysplasia Market

A strategic analysis of the Skeletal Dysplasia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Skeletal Dysplasia Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen, Inc., ARUP Laboratories, AstraZeneca PLC, BioMarin Pharmaceutical Inc., Celgene Corporation, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Skeletal Dysplasia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Achondroplasia, Fibrodysplasia Ossificans Progressive, Hypophosphatasia, Multiple Osteochondromas, and X-linked Hypophosphatemia.
  • Based on Treatment, market is studied across Medication and Surgery.
  • Based on End User, market is studied across Clinic and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing congenital disorders and birth defects
      • 5.1.1.2. Growth in hormone therapy for treatment of skeletal dysplasia
      • 5.1.1.3. Focus on the technological advancements in skeletal dysplasia devices
    • 5.1.2. Restraints
      • 5.1.2.1. Limited treatment options available for skeletal dysplasia
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D and clinical trial for drug development of skeletal dysplasia
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of efficient diagnostic measures and technologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Skeletal Dysplasia Market, by Type

  • 6.1. Introduction
  • 6.2. Achondroplasia
  • 6.3. Fibrodysplasia Ossificans Progressive
  • 6.4. Hypophosphatasia
  • 6.5. Multiple Osteochondromas
  • 6.6. X-linked Hypophosphatemia

7. Skeletal Dysplasia Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Surgery

8. Skeletal Dysplasia Market, by End User

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Hospital

9. Americas Skeletal Dysplasia Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Skeletal Dysplasia Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Skeletal Dysplasia Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals Inc.
  • 3. Amgen, Inc.
  • 4. ARUP Laboratories
  • 5. AstraZeneca PLC
  • 6. BioMarin Pharmaceutical Inc.
  • 7. Celgene Corporation
  • 8. Cipla Inc.
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Novartis AG
  • 13. Regeneron Pharmaceuticals Inc.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. SKELETAL DYSPLASIA MARKET RESEARCH PROCESS
  • FIGURE 2. SKELETAL DYSPLASIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SKELETAL DYSPLASIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SKELETAL DYSPLASIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SKELETAL DYSPLASIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SKELETAL DYSPLASIA MARKET DYNAMICS
  • TABLE 7. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY ACHONDROPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY FIBRODYSPLASIA OSSIFICANS PROGRESSIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY HYPOPHOSPHATASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY MULTIPLE OSTEOCHONDROMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY X-LINKED HYPOPHOSPHATEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. SKELETAL DYSPLASIA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. SKELETAL DYSPLASIA MARKET, FPNV POSITIONING MATRIX, 2023